94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZO

group, the absolute numbers of LYM, ALB, and TBNK (CD3+, CD3+CD4+, CD3+ CD8 +, CD16+CD56+, and CD19+) cell subsets were lower than those in the healthy control group (P < 0.001).A comparison of lymphocyte subpopulations in nasopharyngeal carcinomas at different stages revealed that CD3+CD8+(%) in N3 patients was higher than in N0-2.Patients who acquired metastases had higher CD19+ (%).The multifactorial combination index for the differential diagnosis of NPC, which included PNI, EBV, and immunological status, had a sensitivity of 81.59% and specificity of 96.08%. Conclusions:The nutritional and immune statuses of NPC patients were reduced prior to treatment, and the evaluation of nutritional and immune statuses prior to treatment of patients with NPC at the time of diagnosis is of guiding significance for subsequent anti-tumor treatment, which is worth promoting and applying in the clinic.